• All
  • Events
  • News
  • Press
  • Uncategorized
  • Video

Bordeaux, France / July 7th, 2022 – Peter Nell, Ph.D., was appointed independent board member of TreeFrog Therapeutics. Peter Nell led business development and corporate strategy activities in the cell & gene therapy field over the past ten years and is currently building a new...

We had the chance to interview Teisha Rowland, Ph.D., Principal Scientist at Umoja Biopharma during the ISSCR in San Francisco about the Umoja/TreeFrog partnership. Leading iPSC engineering at Umoja, she comes back on the vision of Umoja, its RACRâ„¢ technology and her interest in TreeFrog's...

Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors. SEATTLE and PESSAC, France / June 10th, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf,...

Throughout 2022, TreeFrog Therapeutics will be connected to strategic international investors through the EIC ScaleUp initiative. Selected among 3,000+ deeptech companies funded by the €10.1 billion EIC innovation programme for European startups and SMEs, TreeFrog Therapeutics joins the EIC Scalingup TOP50 and EIC Growth Club. “TreeFrog...